Status:
RECRUITING
Observation of Inhalation of CXMCI-01 Essential Oil on Patients With Mild Cognitive Impairment
Lead Sponsor:
China Medical University Hospital
Conditions:
Mild Cognitive Impairment
Eligibility:
All Genders
50+ years
Phase:
NA
Brief Summary
Memory declined and cognitive impairment are common complaints in neurology clinics. Before diagnosing as dementia, individuals will undergo a transition period, including mild cognitive impairment (M...
Detailed Description
\< Trial Description and Rationale for Intervention \> Neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), Lewy body dementia (LBD), and frontotemporal dementia (FT...
Eligibility Criteria
Inclusion
- Aged 50 years or older, presenting with memory and cognitive impairment. Diagnosed with Mild Cognitive Impairment (MCI) by a neurologist based on clinical and psychological assessment. Mini-mental state examination(MMSE) ≥ 23 and Clinical Dementia Rating (CDR) = 0.5.
- Neurological consultation: Participants must undergo a neurology consultation, including medical history review, neurological examination, and olfactory function testing.
- No essential oil use within the past month.
Exclusion
- Dementia caused by other conditions, including: Alzheimer's disease, Parkinson's disease, vascular dementia, traumatic brain injury, central nervous system infections or multiple sclerosis
- Cognitive impairment due to brain lesions, such as: brain tumors, hydrocephalus, severe brain atrophy
- Severe metabolic disorders potentially affecting cognitive function, including:
- Uncontrolled hyperthyroidism or hypothyroidism
- Uncorrected electrolyte imbalance
- Liver dysfunction (ALT or AST \> 1.5× normal upper limit)
- Renal dysfunction (Creatinine \> 1.5× normal upper limit)
- Uncontrolled or poorly managed diabetes (Random glucose \> 200 mg/dL and HbA1c \> 8%)
- Uncontrolled or poorly managed hypertension (SBP \> 160 mmHg or DBP \> 100 mmHg)
- Uncorrected vitamin B12 or folate deficiency
- Severe anemia (Hb \< 8 g/dL) or acute bleeding causing Hb \< 8 g/dL
- Current severe infection (fever \> 38°C, ongoing antibiotic use, or abnormal WBC count)
- Body Mass Index (BMI) ≥ 35
- Severe nasal or pharyngeal diseases affecting olfactory function, or history of asthma attacks in the past six months.
- Substance or alcohol abuse within the past two years, meeting DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) criteria.
- Diagnosis of psychiatric disorders within the past year, including: Major depressive disorder, schizophrenia, bipolar disorder (DSM-5 criteria),
- Severe insomnia, defined as:
- (1) Experiencing insomnia symptoms for more than 50% of days per month for at least three months, causing daytime fatigue.
- (2) Use of three or more sleep-related medications (e.g., benzodiazepines or Z-drugs).
- 8\. History of cancer under active treatment. 9. Use of anticholinergic or acetylcholinesterase inhibitor medications. 10.Concurrent use of other neuroprotective therapies, including traditional Chinese medicine or dietary supplements (except for long-term users exceeding three months).
- Allergy to essential oils. 12.Inability to comply with essential oil inhalation procedures. 13.Other conditions deemed inappropriate by the principal investigator. 14.Inability to understand or comply with study procedures, or failure to sign the informed consent form.
Key Trial Info
Start Date :
April 7 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2027
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06902181
Start Date
April 7 2025
End Date
February 1 2027
Last Update
April 10 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Everan Hospital
Taichung, Taiwan, 411001
2
Everan Hospital
Taichung, Taiwan, 411